Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Truong

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
European Urology Focus|May 27, 2018
Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic NomogramMarc A Bjurlin, Audrey Renson, Soroush Rais-Bahrami, et al.
Annals of Surgical Oncology|May 8, 2020
Variation in Adequate Lymph Node Yield for Gastric, Lung, and Bladder Cancer: Attributable to the Surgeon, Pathologist, or Hospital?Christopher T Aquina, Matthew Truong, Carla F Justiniano, et al.
The Journal of Urology|November 20, 2012
Using the epigenetic field defect to detect prostate cancer in biopsy negative patientsMatthew Truong, Bing Yang, Andrew Livermore, et al.
Cancer|October 5, 2017
Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsyMatthew Truong, Bokai Wang, Jennifer B Gordetsky, et al.
Urology Practice|June 10, 2023
Institutional Learning Curve Associated with Implementation of a Magnetic Resonance/Transrectal Ultrasound Fusion Biopsy Program Using PI-RADS™ Version 2: Factors that Influence SuccessMatthew Truong, Eric Weinberg, Gary Hollenberg, et al.
Cancer|September 6, 2013
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancerMatthew Truong, Jon A Slezak, Chee Paul Lin, et al.
Aging|September 13, 2020
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cellsChangyi Lin, Fu-Ju Chou, Jieyang Lu, et al.
European Urology Oncology|June 16, 2019
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance ImagingMatthew Truong, Janet E Baack Kukreja, Soroush Rais-Bahrami, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
European Urology Focus|May 27, 2018
Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic NomogramMarc A Bjurlin, Audrey Renson, Soroush Rais-Bahrami, et al.
Annals of Surgical Oncology|May 8, 2020
Variation in Adequate Lymph Node Yield for Gastric, Lung, and Bladder Cancer: Attributable to the Surgeon, Pathologist, or Hospital?Christopher T Aquina, Matthew Truong, Carla F Justiniano, et al.
The Journal of Urology|November 20, 2012
Using the epigenetic field defect to detect prostate cancer in biopsy negative patientsMatthew Truong, Bing Yang, Andrew Livermore, et al.
Cancer|October 5, 2017
Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsyMatthew Truong, Bokai Wang, Jennifer B Gordetsky, et al.
Urology Practice|June 10, 2023
Institutional Learning Curve Associated with Implementation of a Magnetic Resonance/Transrectal Ultrasound Fusion Biopsy Program Using PI-RADS™ Version 2: Factors that Influence SuccessMatthew Truong, Eric Weinberg, Gary Hollenberg, et al.
Cancer|September 6, 2013
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancerMatthew Truong, Jon A Slezak, Chee Paul Lin, et al.
Aging|September 13, 2020
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cellsChangyi Lin, Fu-Ju Chou, Jieyang Lu, et al.
European Urology Oncology|June 16, 2019
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance ImagingMatthew Truong, Janet E Baack Kukreja, Soroush Rais-Bahrami, et al.
Pageof 3